dostęp otwarty

Tom 14, Nr 3 (2018)
Artykuł przeglądowy
Opublikowany online: 2018-11-21
Pobierz cytowanie

Przegląd czynników ryzyka krwotoku wewnątrzczaszkowego po dożylnym leczeniu trombolitycznym udaru niedokrwiennego mózgu

Małgorzata Wichlińska-Lubińska
Pol. Przegl. Neurol 2018;14(3):156-164.

dostęp otwarty

Tom 14, Nr 3 (2018)
Artykuły przeglądowe
Opublikowany online: 2018-11-21

Streszczenie

Mimo że dożylne leczenie trombolityczne jest skutecznym i obecnie powszechnie akceptowanym sposobem postępowania w ostrej fazie udaru niedokrwiennego mózgu, zastosowanie tej metody nadal pozostaje nie w pełni wykorzystane. Jednym z ważniejszych tego powodów (poza ograniczeniami wynikającymi z protokołu leczenia) wydaje się obawa przed powikłaniami krwotocznymi, zwłaszcza wewnątrzczaszkowymi. Celem niniejszego artykułu jest zbiorcze przedstawienie badań dotyczących czynników ryzyka wewnątrzczaszkowych powikłań krwotocznych po leczeniu trombolitycznym. Analiza ma przybliżyć i uporządkować zagadnienia oraz uświadomić czytelnikom, że wyniki badań nie są jednoznaczne i nie powinny negatywnie wpływać na podejmowanie decyzji o leczeniu za pomocą rekombinowanego tkankowego aktywatora plazminogenu.

Streszczenie

Mimo że dożylne leczenie trombolityczne jest skutecznym i obecnie powszechnie akceptowanym sposobem postępowania w ostrej fazie udaru niedokrwiennego mózgu, zastosowanie tej metody nadal pozostaje nie w pełni wykorzystane. Jednym z ważniejszych tego powodów (poza ograniczeniami wynikającymi z protokołu leczenia) wydaje się obawa przed powikłaniami krwotocznymi, zwłaszcza wewnątrzczaszkowymi. Celem niniejszego artykułu jest zbiorcze przedstawienie badań dotyczących czynników ryzyka wewnątrzczaszkowych powikłań krwotocznych po leczeniu trombolitycznym. Analiza ma przybliżyć i uporządkować zagadnienia oraz uświadomić czytelnikom, że wyniki badań nie są jednoznaczne i nie powinny negatywnie wpływać na podejmowanie decyzji o leczeniu za pomocą rekombinowanego tkankowego aktywatora plazminogenu.

Pobierz cytowanie

Słowa kluczowe

czynniki ryzyka; udar niedokrwienny mózgu; leczenie trombolityczne; krwotok wewnątrzczaszkowy

Informacje o artykule
Tytuł

Przegląd czynników ryzyka krwotoku wewnątrzczaszkowego po dożylnym leczeniu trombolitycznym udaru niedokrwiennego mózgu

Czasopismo

Polski Przegląd Neurologiczny

Numer

Tom 14, Nr 3 (2018)

Typ artykułu

Artykuł przeglądowy

Strony

156-164

Data publikacji on-line

2018-11-21

Rekord bibliograficzny

Pol. Przegl. Neurol 2018;14(3):156-164.

Słowa kluczowe

czynniki ryzyka
udar niedokrwienny mózgu
leczenie trombolityczne
krwotok wewnątrzczaszkowy

Autorzy

Małgorzata Wichlińska-Lubińska

Referencje (104)
  1. Jauch EC, Saver JL, Adams HP, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3): 870–947.
  2. Śledzińska-Dźwigał M, Kobayashi A, Członkowska A, et al. Czynniki ryzyka wewnątrzczaszkowych powikłań krwotocznych związanych z leczeniem trombolitycznym udaru niedokrwiennego mózgu. Terapia. 2012; 1: 14–20.
  3. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001; 32(6): 1330–1335.
  4. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006; 37(2): 556–561.
  5. Paszkiewicz-Woźniak D. Postępowanie w przypadku powikłań leczenia trombolitycznego udaru niedokrwiennego mózgu. Neurologia po Dyplomie. 2014; 9(6): 25–48.
  6. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 1995; 333(24): 1581–1588.
  7. The National Institute of Neurological Disorders and rt-PA Study Group.. Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke. Stroke. 1997; 28(11): 2109–2118.
  8. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13): 1017–1025.
  9. Hacke W, Kaste M, Fieschi C, et al. Second European-Australasian Acute Stroke Study Investigators.. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352(9136): 1245–1251.
  10. Wahlgren N, Ahmed N, Eriksson N, et al. Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008; 39(12): 3316–3322.
  11. Seet RCS, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis. 2012; 34(2): 106–114.
  12. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008; 79(10): 1093–1099.
  13. Rubiera M, Alvarez-Sabín J, Ribo M, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005; 36(7): 1452–1456.
  14. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282(21): 2019–2026.
  15. Hacke W, Kaste M, Bluhmki E, et al. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317–1329.
  16. Hacke W, Donnan G, Fieschi C, et al. ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363(9411): 768–774.
  17. Thomalla G, Sobesky J, Köhrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007; 38(2): 313–318.
  18. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002; 105(14): 1679–1685.
  19. Lansberg MG, Albers GW, Wijman CAC. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007; 24(1): 1–10.
  20. Cocho D, Borrell M, Martí-Fàbregas J, et al. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke. 2006; 37(4): 996–999.
  21. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA. 2004; 292(15): 1831–1838.
  22. Simon JE, Sandler DL, Pexman JH, et al. Calgary Stroke Programme. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? The Calgary experience. Age Ageing. 2004; 33(2): 143–149.
  23. Berrouschot J, Röther J, Glahn J, et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or = 80 years) stroke patients. Stroke. 2005; 36(11): 2421–2425.
  24. Mouradian MS, Senthilselvan A, Jickling G, et al. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry. 2005; 76(9): 1234–1237.
  25. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age — a systematic review across cohort studies. Age Ageing. 2006; 35(6): 572–580.
  26. Sylaja PN, Cote R, Buchan AM, et al. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006; 77(7): 826–829.
  27. Pundik S, McWilliams-Dunnigan L, Blackham KL, et al. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke. J Stroke Cerebrovasc Dis. 2008; 17(5): 266–272.
  28. Sarikaya H. Safety and efficacy of thrombolysis with intravenous alteplase in older stroke patients. Drugs Aging. 2013; 30(4): 227–234.
  29. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997; 28(5): 957–960.
  30. Jaillard A, Cornu C, Durieux A, et al. MAST-E Group. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. Stroke. 1999; 30(7): 1326–1332.
  31. Derex L, Hermier M, Adeleine P, et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry. 2005; 76(1): 70–75.
  32. Cucchiara B, Kasner SE, Tanne D, et al. SAINT Investigators. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke. 2009; 40(9): 3067–3072.
  33. Hill MD, Buchan AM. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005; 172(10): 1307–1312.
  34. Derex L, Nighoghossian N, Hermier M, et al. Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator. Stroke. 2003; 34(2): 458–463.
  35. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke. 2005; 36(3): 602–606.
  36. Gilligan AK, Markus R, Read S, et al. Australian Streptokinase Trial Investigators. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke. 2002; 33(9): 2236–2242.
  37. Larrue V, von Kummer R R, Müller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001; 32(2): 438–441.
  38. Seet RCS, Zhang Yi, Wijdicks EF, et al. Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. Arch Neurol. 2011; 68(11): 1454–1458.
  39. Uyttenboogaart M, Koch MW, Koopman K, et al. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008; 65(5): 607–611.
  40. Schmülling S, Rudolf J, Strotmann-Tack T, et al. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2003; 16(3): 183–190.
  41. Bravo Y, Martí-Fàbregas J, Cocho D, et al. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis. Cerebrovasc Dis. 2008; 26(2): 126–133.
  42. Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010; 67(5): 559–563.
  43. Ruecker M, Matosevic B, Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology. 2012; 79(1): 31–38.
  44. Kim YD, Lee JH, Jung YoH, et al. Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci. 2010; 298(1–2): 101–105.
  45. Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010; 41(7): 1450–1458.
  46. Vergouwen MDI, Casaubon LK, Swartz RH, et al. Investigators of the Registry of the Canadian Stroke Network. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke. 2011; 42(4): 1041–1045.
  47. Alexandrov AV, Demchuk AM, Burgin WS, et al. CLOTBUST Investigators. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000; 31(8): 1812–1816.
  48. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003; 34(12): 2847–2850.
  49. Martí-Fàbregas J, Bravo Y, Cocho D, et al. Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials. Cerebrovasc Dis. 2007; 23(2–3): 85–90.
  50. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283(9): 1145–1150.
  51. Aleu A, Mellado P, Lichy C, et al. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke. 2007; 38(2): 417–422.
  52. Levy DE, Brott TG, Haley EC, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994; 25(2): 291–297.
  53. Hacke W, Albers G, Al-Rawi Y, et al. DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005; 36(1): 66–73.
  54. Haley EC, Lyden PD, Johnston KC, et al. TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005; 36(3): 607–612.
  55. Barber PA, Demchuk AM, Zhang J, et al. ASPECTS Study Group. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000; 355(9216): 1670–1674.
  56. Patel SC, Levine SR, Tilley BC, et al. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001; 286(22): 2830–2838.
  57. Roberts HC, Dillon WP, Furlan AJ, et al. Computed tomographic findings in patients undergoing intra-arterial thrombolysis for acute ischemic stroke due to middle cerebral artery occlusion: results from the PROACT II trial. Stroke. 2002; 33(6): 1557–1565.
  58. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998; 65(1): 1–9.
  59. Dubey N, Bakshi R, Wasay M, et al. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging. 2001; 11(2): 184–188.
  60. Lyden P. Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke. 2003; 34(3): 821–822.
  61. Wardlaw JM, Sandercock P, Lindley RI. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. The Lancet. 2012; 379(9834): 2352–2363.
  62. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. MR Stroke Group. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke. 2006; 37(10): 2463–2466.
  63. Palumbo V, Boulanger JM, Hill MD, et al. CASES Investigators. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology. 2007; 68(13): 1020–1024.
  64. Tisserand M, Le Guennec L, Touzé E, et al. Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis. Neurology. 2011; 76(15): 1288–1295.
  65. Lyerly MJ, Houston JT, Boehme AK, et al. Safety of intravenous tissue plasminogen activator administration with computed tomography evidence of prior infarction. J Stroke Cerebrovasc Dis. 2014; 23(6): 1657–1661.
  66. Lindley RI, Wardlaw JM, Whiteley WN, et al. IST-3 Collaborative Group. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial. Stroke. 2015; 46(3): 746–756.
  67. Tong DC, Adami A, Moseley ME, et al. Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke. Stroke. 2000; 31(10): 2378–2384.
  68. Tong D, Adami A, Moseley M, et al. Prediction of Hemorrhagic Transformation Following Acute Stroke. Archives of Neurology. 2001; 58(4): 587–593.
  69. Selim M, Fink JN, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002; 33(8): 2047–2052.
  70. Singer OC, Kurre W, Humpich MC, et al. MR Stroke Study Group Investigators. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS. Stroke. 2009; 40(8): 2743–2748.
  71. Albers GW, Thijs VN, Wechsler L, et al. DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006; 60(5): 508–517.
  72. Vo KD, Santiago F, Lin W, et al. MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. AJNR Am J Neuroradiol. 2003; 24(4): 674–679.
  73. Kim EY, Na DG, Kim SS, et al. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. AJNR Am J Neuroradiol. 2005; 26(5): 1050–1055.
  74. Latour LL, Kang DW, Ezzeddine MA, et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol. 2004; 56(4): 468–477.
  75. Kassner A, Roberts T, Taylor K, et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol. 2005; 26(9): 2213–2217.
  76. Alsop DC, Makovetskaya E, Kumar S, et al. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke. 2005; 36(4): 746–750.
  77. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke. 2004; 35(11, Suppl 1): 2659–2661.
  78. Hermier M, Nighoghossian N, Derex L, et al. Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab. 2003; 23(11): 1362–1370.
  79. Ohta H, Nakano S, Yokogami K, et al. Appearance of early venous filling during intra-arterial reperfusion therapy for acute middle cerebral artery occlusion: a predictive sign for hemorrhagic complications. Stroke. 2004; 35(4): 893–898.
  80. Nighoghossian N, Hermier M, Adeleine P, et al. Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study. Stroke. 2002; 33(3): 735–742.
  81. Fan YuH, Zhang L, Lam WWM, et al. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke. 2003; 34(10): 2459–2462.
  82. Chalela JA, Kang DW, Warach S. Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging. 2004; 14(1): 54–57.
  83. Derex L, Nighoghossian N, Hermier M, et al. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis. 2004; 17(2–3): 238–241.
  84. Kakuda W, Thijs VN, Lansberg MG, et al. DEFUSE Investigators. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology. 2005; 65(8): 1175–1178.
  85. Fiehler J, Albers GW, Boulanger JM, et al. MR STROKE Group. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007; 38(10): 2738–2744.
  86. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30(1): 34–39.
  87. Lindsberg PJ, Soinne L, Roine RO, et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke. 2003; 34(6): 1443–1449.
  88. Bruno A, Levine SR, Frankel MR, et al. NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002; 59(5): 669–674.
  89. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke. 2008; 39(10): 2749–2755.
  90. Lyrer PA, Fluri F, Gisler D, et al. Renal function and outcome among stroke patients treated with IV thrombolysis. Neurology. 2008; 71(19): 1548–1550.
  91. Naganuma M, Koga M, Shiokawa Y, et al. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis. 2011; 31(2): 123–129.
  92. Chao TH, Lin TC, Shieh Y, et al. Intracerebral hemorrhage after thrombolytic therapy in acute ischemic stroke patients with renal dysfunction. Eur Neurol. 2013; 70(5–6): 316–321.
  93. Agrawal V, Rai B, Fellows J, et al. In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke. Nephrol Dial Transplant. 2010; 25(4): 1150–1157.
  94. Power A, Epstein D, Cohen D, et al. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke. Cerebrovasc Dis. 2013; 35(1): 45–52.
  95. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001; 57(9): 1603–1610.
  96. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003; 107(4): 598–603.
  97. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003; 34(1): 40–46.
  98. Castellanos M, Leira R, Serena J, et al. Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke. Stroke. 2004; 35(7): 1671–1676.
  99. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004; 35(9): 2123–2127.
  100. Trouillas P, Derex L, Philippeau F, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke. 2004; 35(6): 1323–1328.
  101. Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology. 2013; 80(13): 1216–1224.
  102. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke. 2007; 38(9): 2491–2495.
  103. Millan M, Sobrino T, Castellanos M, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke. 2007; 38(1): 90–95.
  104. Micieli G, Marcheselli S, Tosi PA. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag. 2009; 5(1): 397–409.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel. +48 58 320 94 94, faks +48 58 320 94 60, e-mail: viamedica@viamedica.pl